Nwam LLC Raises Holdings in Novo Nordisk A/S $NVO

Nwam LLC lifted its position in shares of Novo Nordisk A/S (NYSE:NVO) by 331.4% during the first quarter, Holdings Channel reports. The firm owned 20,662 shares of the company’s stock after acquiring an additional 15,872 shares during the quarter. Nwam LLC’s holdings in Novo Nordisk A/S were worth $759,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in NVO. Godfrey Financial Associates Inc. acquired a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at approximately $25,000. WealthCollab LLC increased its holdings in shares of Novo Nordisk A/S by 93.5% in the 4th quarter. WealthCollab LLC now owns 538 shares of the company’s stock valued at $27,000 after acquiring an additional 260 shares during the period. American National Bank & Trust purchased a new stake in Novo Nordisk A/S in the 4th quarter valued at $28,000. Maseco LLP acquired a new stake in Novo Nordisk A/S during the 4th quarter worth $29,000. Finally, Jackson Grant Investment Advisers Inc. acquired a new stake in Novo Nordisk A/S during the 4th quarter worth $29,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Key Stories Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: The European Commission approved Novo Nordisk’s once-daily oral Wegovy pill for obesity, making it the first GLP-1 tablet cleared for weight management in the EU and expanding the company’s addressable market. Reuters article on EU approval
• Positive Sentiment: Multiple reports said the oral Wegovy approval could help Novo Nordisk extend its lead over Eli Lilly in obesity treatment, reinforcing optimism around the company’s long-term growth in diabetes and weight-loss therapies. Pharmaceutical Technology article on competition with Lilly
• Positive Sentiment: Analysts and market commentary pointed to improved growth expectations and higher fair value estimates after the approval, signaling that sentiment around Novo’s obesity pipeline has improved. Yahoo Finance article on fair value estimate
• Neutral Sentiment: Novo also announced a new Phase 3 heart failure–obesity trial, which supports its cardiometabolic strategy but is still early-stage and unlikely to affect near-term results. TipRanks article on trial update
• Negative Sentiment: Separate news that Sun Pharma won approval in South Africa for a generic version of semaglutide highlights ongoing competitive and copycat-drug pressure on Novo Nordisk’s key products. Reuters article on generic Ozempic approval
• Negative Sentiment: Zacks Research downgraded Novo Nordisk from hold to strong sell, showing that not all analysts are convinced the stock’s recent strength will continue. Tickerreport article on downgrade

Analyst Ratings Changes

A number of research analysts have commented on NVO shares. Zacks Research lowered shares of Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research note on Monday. Wall Street Zen lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Saturday, June 20th. Weiss Ratings downgraded Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, April 22nd. Citigroup reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research report on Tuesday, May 12th. Finally, Wolfe Research began coverage on Novo Nordisk A/S in a report on Thursday, March 26th. They issued a “peer perform” rating on the stock. Five investment analysts have rated the stock with a Buy rating, sixteen have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Novo Nordisk A/S has a consensus rating of “Hold” and an average price target of $65.56.

Novo Nordisk A/S Trading Up 1.9%

Shares of Novo Nordisk A/S stock opened at $51.50 on Friday. The firm has a market cap of $229.96 billion, a price-to-earnings ratio of 12.09, a price-to-earnings-growth ratio of 4.61 and a beta of 0.77. Novo Nordisk A/S has a 52-week low of $35.12 and a 52-week high of $71.79. The company’s 50-day simple moving average is $46.01 and its 200-day simple moving average is $45.79. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.The company had revenue of $10.85 billion for the quarter. As a group, equities research analysts anticipate that Novo Nordisk A/S will post 3.38 earnings per share for the current year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.